An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs BAY 1143572 (Primary)
- Indications Leukaemia
- Focus Adverse reactions
- Sponsors Bayer
- 22 Aug 2017 Status changed from active, no longer recruiting to completed.
- 03 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.